ReviewMicroorganisms2025
Probiotic Supplementation and Inflammatory Status in Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparative Effects of Probiotics, Prebiotics, and Synbiotics on Clinical Outcomes in Coronary Artery Disease: A Systematic Review and Meta-Analysis.Probiotics and antimicrobial proteins · 2026Review
- Intestinal Flora and Myocarditis: Potential Mechanisms and Therapeutic Strategies Affecting Disease Progression and Cardiac Function.International journal of molecular sciences · 2026Review
- Metabolic syndrome and a broken heart: trust your gut or risk your heart.American journal of physiology. Heart and circulatory physiology · 2026Review
- Antioxidant and Anti-Inflammatory Activities of Probiotic Strains.International journal of molecular sciences · 2026Review
- Microbiota-Mediated Crosstalk Between the Gut and the Vascular System: Protective Effects of Novel Postbiotic Formulations on Human Endothelial and Vascular Smooth Muscle Cells.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD), a major contributor to healthcare burdens worldwide, is closely linked with chronic inflammation. Probiotic supplementation has been investigated for its potential to modulate inflammatory responses, yet its role in patients with CAD remains unclear. To address this, we conducted a systematic review and meta-analysis following PRISMA guidelines, with literature searches performed across PubMed, EMBASE, and Cochrane CENTRAL up to 19 March 2025. Eligible studies included randomized controlled trials that examined the effects of probiotics, prebiotics, or synbiotics in patients with CAD or ischemic heart disease. Study quality was assessed using the Cochrane Collaboration tool, and standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated for pooled outcomes. A total of five randomized controlled trials involving 256 patients with CAD were included. The meta-analysis demonstrated significant improvements in inflammatory biomarkers among participants receiving probiotics compared with those in the placebo group. Specifically, probiotic supplementation led to greater reductions in high-sensitivity C-reactive protein (pooled SMD [pSMD] = -0.61; 95% confidence interval [CI]: -0.87 to -0.36) and malondialdehyde (pSMD = -0.52; 95% CI: -0.91 to -0.12). No significant increase was observed in nitric oxide (pSMD = 0.91; 95% CI: -3.72 to 5.54) or total antioxidant capacity (pSMD = 0.35; 95% CI: -2.16 to 2.86) in the intervention group over control. No significant difference was found in glutathione levels between the two groups (pSMD = 0.01; 95% CI: -0.51 to 0.53). Overall, these findings suggest that probiotic supplementation exerts a beneficial effect on inflammatory status in patients with CAD. The evidence highlights its potential in reducing systemic inflammation and oxidative stress, as reflected by improvements in high-sensitivity C-reactive protein and malondialdehyde.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.